ReviewMolecules (Basel, Switzerland)2015
Role and Regulation of Glutathione Metabolism in Plasmodium falciparum.
Review in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Association of reduced glutathione levels with Plasmodium falciparum and Plasmodium vivax malaria: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Glutathione Relevance in the Response of CiliateBiology · 2026Article
- Revisiting Glutathione Transferases ofPharmaceuticals (Basel, Switzerland) · 2026Review
- In Vitro, In Silico, and In Vivo Evaluation of Antiplasmodial Activity of Ursodeoxycholic Acid Following GNPS Dereplication of an ActivePharmaceuticals (Basel, Switzerland) · 2026Article
- Glutathione redox system as a therapeutic target for Plasmodium: Opportunities, Challenges, and future perspectives.Folia microbiologica · 2026Review
- Double Mutations inbioRxiv : the preprint server for biology · 2026Article
- A Fe-incorporated bioreactor platform exhibiting antimalarial activity and enhanced response to artemisinin.Antimicrobial agents and chemotherapy · 2026Article
- Fifty shades of iron: Unorthodox mechanisms of iron acquisition and utilization in blood-stage Plasmodium parasites.PLoS pathogens · 2026Review
- Shared host, distinct invaders: metabolomic footprints of plasmodium and babesia in host red cells.Current opinion in hematology · 2025Review
- Synergistic activity of RSL3 and Pyrimethamine to inhibit the proliferation ofAntimicrobial agents and chemotherapy · 2025Article
- Thrombocytopenia and Epistaxis ComplicatingCase reports in medicine · 2025Article
- Antimalarial Activity of Aqueous Extracts of Nasturtium (Molecules (Basel, Switzerland) · 2024Article
- Article
- Marine-DerivedMicroorganisms · 2023Article
- In Vitro Antiprotozoal Activity ofBiology · 2023Article
- Engineered symbiotic bacteria interfering Nosema redox system inhibit microsporidia parasitism in honeybees.Nature communications · 2023Article
- Elucidating parasite and host-cell factors enabling Babesia infection in sickle red cells under hypoxic/hyperoxic conditions.Blood advances · 2023Article
- Peroxide Antimalarial Drugs Target Redox Homeostasis inACS infectious diseases · 2022Article
- The Metabolomic Profiles of Sera of Mice Infected with Plasmodium berghei and Treated by Effective Fraction of Naja naja oxiana UsingActa parasitologica · 2021Article
- Reactive Oxygen Species as the Brainbox in Malaria Treatment.Antioxidants (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria in humans is caused by one of five species of obligate intracellular protozoan parasites of the genus Plasmodium. P. falciparum causes the most severe disease and is responsible for 600,000 deaths annually, primarily in Sub-Saharan Africa. It has long been suggested that during their development, malaria parasites are exposed to environmental and metabolic stresses. One strategy to drug discovery was to increase these stresses by interfering with the parasites' antioxidant and redox systems, which may be a valuable approach to disease intervention. Plasmodium possesses two redox systems-the thioredoxin and the glutathione system-with overlapping but also distinct functions. Glutathione is the most abundant low molecular weight redox active thiol in the parasites existing primarily in its reduced form representing an excellent thiol redox buffer. This allows for an efficient maintenance of the intracellular reducing environment of the parasite cytoplasm and its organelles. This review will highlight the mechanisms that are responsible for sustaining an adequate concentration of glutathione and maintaining its redox state in Plasmodium. It will provide a summary of the functions of the tripeptide and will discuss the potential of glutathione metabolism for drug discovery against human malaria parasites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.